ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public OfferingIRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share.
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate UpdateRevenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023
ReShape Lifesciences Announces 1-for-58 Reverse Stock SplitEffective as of Commencement of Trading on September 23, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of ShareholdersNEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to ReShape shareholders.
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ReShape Lifesciences Inc. (
NASDAQRSLS) and Vyome Therapeutics, Inc. is fair to ReShape shareholders. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million.
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad MedisysReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership AlternativesIRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group LLC, to act as the Company’s exclusive financial advisor to identify potential strategic merger and acquisition partnership alternatives. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.
